Business models that were used to create current value are no longer going to be effective going forward.
Jan 1, 2011
By:
G. Steven Burrill
Business models that were used to create current value are no longer going to be effective going forward.
|
Biotech's mid-sized elites position themselves for growth.
Oct 1, 2010
By:
G. Steven Burrill
Biotech's mid-sized elites position themselves for growth.
|
After a bright start to the year, some of biotech's blue chip companies have seen their early gains turn into losses.
Jul 1, 2010
By:
G. Steven Burrill
After a bright start to the year, some of biotech's blue chip companies have seen their early gains turn into losses.
|
As the capital markets in the US and globally continue to strengthen, the biotech industry can expect to see a rise in initial public offerings this year.
Apr 1, 2010
By:
G. Steven Burrill
As the capital markets in the US and globally continue to strengthen, the biotech industry can expect to see a rise in initial public offerings this year.
|
The companies that have survived the financial meltdown are well placed to adapt to the new environment that we now are entering.
Jan 1, 2010
By:
G. Steven Burrill
The companies that have survived the financial meltdown are well placed to adapt to the new environment that we now are entering.
|
Biotech impressed investors with positive drug data, strong drug sales and earnings, and partnering deals.
Oct 1, 2009
By:
G. Steven Burrill
Biotech impressed investors with positive drug data, strong drug sales and earnings, and partnering deals.
|
Although the markets closed on a positive note in May, it will still take many more months before biotech starts on the road to full recovery.
Jul 1, 2009
By:
G. Steven Burrill
Although the markets closed on a positive note in May, it will still take many more months before biotech starts on the road to full recovery.
|
Big biotechs will do just fine in the ongoing financial crisis, but the smaller companies will have more difficulty weathering the storm.
Apr 1, 2009
By:
G. Steven Burrill
Big biotechs will do just fine in the ongoing financial crisis, but the smaller companies will have more difficulty weathering the storm.
|
Small biotechs were forced to restructure and downsize.
Jan 1, 2009
By:
G. Steven Burrill
Small biotechs were forced to restructure and downsize.
|
|
